In a multi-media feature on its website, the Canadian Institutes for Health Research (CIHR) has highlighted the role of NanoVation Therapeutics^TM Co-Founder and Board Chair Dr. Pieter Cullis in developing the lipid nanoparticle (LNP) delivery technology that has enabled the development of mRNA-based gene therapies, as evidenced by the efficacy of the Pfizer-BioNTech COVID 19 vaccine.